Welcome to our dedicated page for Paysign news (Ticker: PAYS), a resource for investors and traders seeking the latest updates and insights on Paysign stock.
Paysign, Inc. (NASDAQ: PAYS) is a fintech and healthcare-focused company whose news flow centers on patient affordability programs, donor compensation solutions and integrated payment processing for the life sciences industries. News about PAYS often highlights developments in its pharma patient affordability business, plasma donor compensation programs and the performance of its card-based payment platform.
Company press releases frequently cover quarterly financial results, where Paysign reports on total revenues, plasma revenue, pharma patient affordability revenue, gross profit, operating expenses, EBITDA and Adjusted EBITDA. These updates also describe trends in plasma center counts, the number of active pharma patient affordability programs, processed claims and the mix of revenue between plasma, pharma patient affordability and other prepaid and incentive programs.
Another recurring theme in Paysign news is the expansion and refinement of its patient affordability solutions. The company has discussed the growth of pharmaceutical copay programs, the adoption of its Dynamic Business Rules technology to address copay maximizers, and the scale of patient and client savings associated with these programs. Announcements have also described the opening of a patient service support center to increase support capacity for the patient affordability business.
Paysign news items also include participation in investor conferences, board and leadership updates and information about engagement and management platforms for life sciences. For investors, analysts and industry participants, the PAYS news page provides a centralized view of earnings releases, operational milestones, program expansions and corporate governance developments tied to the company’s fintech healthcare ecosystem.
Users interested in PAYS can use this news feed to review historical announcements on plasma and pharma program growth, cardholder and program metrics, litigation and settlement updates, and the company’s commentary on its strategic focus within payment processing and healthcare-related markets.
Paysign (NASDAQ: PAYS) will host its fourth quarter and full year 2025 earnings call on Tuesday, March 24, 2026 at 5:00 p.m. ET. Investors can join via U.S. and international dial-ins or a live webcast. Replay is available through June 24, 2026.
Financial professionals who wish to ask questions must register by emailing ir@paysign.com by 5:00 p.m. ET on Friday, March 20, 2026.
Paysign (NASDAQ: PAYS) will present at the Oppenheimer 11th Annual Emerging Growth Conference, held February 3-4, 2026, in a virtual format. The conference features one-on-one and small-group meetings with emerging companies across technology, industrial growth and consumer sectors. Paysign’s CFO Jeff Baker will host one-on-one investor meetings on Tuesday, February 3, 2026. Investors interested in attending are instructed to contact their Oppenheimer representative to register.
Paysign (NASDAQ: PAYS) reported 2025 patient affordability results showing material growth and measurable savings. The company exited 2025 with 131 active programs (added 55 in 2025), a >70% increase versus 2024, and supported >840,000 unique patients. Paysign said its Dynamic Business Rules feature identifies impacted claims on first fill with 97% accuracy and helped mitigate copay maximizers, saving pharmaceutical program sponsors more than $325 million in 2025 (an increase of >200% from 2024). Paysign also reported assisting clients in delivering more than $950 million toward prescription fulfillment expenses in 2025.
The release frames these metrics as evidence of expanded healthcare presence and enhanced value delivery to patients and pharmaceutical sponsors.
Paysign (NASDAQ: PAYS) will present at the 17th Annual Southwest IDEAS Investor Conference in Dallas, Texas on November 19–20, 2025. The invitation-only conference connects public companies with institutional investors via one-on-one and group meetings.
Paysign's CFO Jeff Baker will present on Thursday, November 20, 2025 and is available for one-on-one meetings during the event.
Paysign (NASDAQ: PAYS) reported record Q3 2025 results with $21.60M revenue, up 41.6% year-over-year, and net income of $2.22M (diluted EPS $0.04), up 54.2%. Adjusted EBITDA was $5.04M (23.3% margin), up 78.1%. Pharma patient affordability revenue grew 141.9% to $7.92M with 105 active programs at quarter end (118 at Oct 31). Plasma revenue rose 12.4% to $12.86M with 595 centers. Ended Q3 with $7.53M unrestricted cash and zero bank debt; unrestricted cash was reduced by timing on $9.36M passthrough claim items. Updated 2025 guidance: revenue $80.5M–$81.5M, net income $7.0M–$8.0M, Adjusted EBITDA $19M–$20M.
Paysign (NASDAQ: PAYS) will host its third quarter 2025 earnings call on Wednesday, November 12, 2025 at 5:00 p.m. ET. The company will discuss third-quarter results and answer questions from registered financial professionals.
Participant details: U.S. dial-in 877.407.2988; International +1.201.389.0923; Webcast available live. Replay: dial 877.660.6853 or +1.201.612.7415, Conference ID 13756404; replay available through May 12, 2026. To ask questions live, financial professionals must register by emailing ir@paysign.com by 5:00 p.m. ET on Friday, November 7, 2025.
Paysign (NASDAQ: PAYS), a provider of patient affordability programs and donor compensation solutions, has appointed Jose Garcia as Executive Vice President of Life Science Solutions. Garcia, with over 20 years of executive experience, will lead the market strategy for the company's engagement and management solutions in life sciences.
Prior to joining Paysign, Garcia served as Vice President of Client Relationships at QualTex Laboratories, where he strengthened partnerships in blood and plasma collection industries. He previously held VP of Sales positions at BioBridge Global companies, QualTex and GenCure, expanding their life sciences presence.
Paysign (NASDAQ: PAYS) has announced the opening of a new 30,000 square foot patient service support center in Henderson, Nevada. The expansion increases the company's support capacity by 4x to meet growing demand in its patient affordability business.
The facility will enhance Paysign's ability to provide dedicated support specialists for individual programs and clients, leveraging its proprietary Dynamic Business Rules technology to optimize copay assistance programs. The company's patient affordability segment has shown remarkable growth, with revenues increasing 190% year-over-year in Q2 2025.
Paysign (NASDAQ: PAYS), a provider of payment solutions for life sciences industries, has announced its participation in the ninth annual Lake Street Best Ideas Growth BIG9 Conference on September 11, 2025. The invitation-only event facilitates interactions between small-cap companies and top institutional investors.
Chief Financial Officer Jeff Baker will represent Paysign at the conference, conducting one-on-one and group meetings with institutional investors throughout the event.
Paysign (NASDAQ: PAYS), a provider of patient affordability programs and payment solutions for life sciences industries, has appointed Dan Henry as Chairman of the Board. Henry succeeds Mark Newcomer, who will continue as President and CEO. Henry, who has served on Paysign's board since 2018, brings over 30 years of fintech leadership experience.
Henry's extensive background includes co-founding Euronet Worldwide, serving as CEO of NetSpend Corporation where he led its IPO and $1.4 billion acquisition by TSYS, and most recently serving as CEO of Green Dot Corporation. He currently chairs Paysign's Executive Compensation Committee and holds a B.S. in Business Administration from the University of Missouri.